Diagnosis and Management of Acute HIV Infection

Infectious Disease Clinics of North America

Volumn 21, Issue 1, 2007, Pages 19-48

  Zetola, Nicola M ^a   Pilcher, Christopher D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE DISEASE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG WITHDRAWAL; EPIDEMIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFECTION CONTROL; LABORATORY TEST; MALE HOMOSEXUAL; MENTAL DISEASE; NUCLEIC ACID AMPLIFICATION; PATHOGENESIS; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; REVIEW; SCREENING TEST; SEXUALLY TRANSMITTED DISEASE; SYMPTOMATOLOGY; VIRUS LOAD; VIRUS TRANSMISSION;

ACUTE DISEASE; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 34248351488     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.01.008     Document Type: Review

References (172)

1. Miller C.J., Li Q., Abel K., et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 79 14 (2005) 9217-9227
2. Cole A.M. Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 306 (2006) 199-230
3. Pope M., and Haase A.T. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 9 7 (2003) 847-852
4. Fleming D.T., and Wasserheit J.N. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 75 1 (1999) 3-17
5. Royce R.A., Sena A., Cates Jr. W., et al. Sexual transmission of HIV. N Engl J Med 336 15 (1997) 1072-1078
6. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5 10 (2005) 783-792
7. Doms R.W. Chemokine receptors and HIV entry. AIDS 15 Suppl 1 (2001) S34-S35
8. McNearney T., Hornickova Z., Kloster B., et al. Evolution of sequence divergence among human immunodeficiency virus type 1 isolates derived from a blood donor and a recipient. Pediatr Res 33 1 (1993) 36-42
9. Roos M.T., Lange J.M., de Goede R.E., et al. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis 165 3 (1992) 427-432
10. Zhang L.Q., MacKenzie P., Cleland A., et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 67 6 (1993) 3345-3356
11. Amedee A.M., Lacour N., Gierman J.L., et al. Genotypic selection of simian immunodeficiency virus in macaque infants infected transplacentally. J Virol 69 12 (1995) 7982-7990
12. Wolinsky S.M., Korber B.T., Neumann A.U., et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272 5261 (1996) 537-542
13. Delwart E., Magierowska M., Royz M., et al. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS 16 2 (2002) 189-195
14. Veazey R.S., Mansfield K.G., Tham I.C., et al. Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol 74 23 (2000) 11001-11007
15. Pandrea I., Apetrei C., Gordon S.N., et al. Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood 109 3 (2007) 1069-1076
16. Locher C.P., Witt S.A., Kassel R., et al. Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation. J Gen Virol 86 Pt 4 (2005) 1171-1179
17. Veazey R., and Lackner A. The mucosal immune system and HIV-1 infection. AIDS Rev 5 4 (2003) 245-252
18. Picker L.J. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol 18 4 (2006) 399-405
19. Zhang Z., Schuler T., Zupancic M., et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286 5443 (1999) 1353-1357
20. Li Q., Duan L., Estes J.D., et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434 7037 (2005) 1148-1152
21. Daar E.S., Little S., Pitt J., et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 134 1 (2001) 25-29
22. Picker L.J., Hagen S.I., Lum R., et al. Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med 200 10 (2004) 1299-1314
23. Mattapallil J.J., Douek D.C., Hill B., et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434 7037 (2005) 1093-1097
24. Brenchley J.M., Schacker T.W., Ruff L.E., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200 6 (2004) 749-759
25. Mehandru S., Poles M.A., Tenner-Racz K., et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200 6 (2004) 761-770
26. Veazey R.S., Marx P.A., and Lackner A.A. Vaginal CD4+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J Infect Dis 187 5 (2003) 769-776
27. Pilcher C.D., Shugars D.C., Fiscus S.A., et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 15 7 (2001) 837-845
28. Fiebig E.W., Wright D.J., Rawal B.D., et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17 13 (2003) 1871-1879
29. Pilcher C.D., Tien H.C., Eron Jr. J.J., et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 189 10 (2004) 1785-1792
30. Fiscus SA, Pilcher CD, Miller W, et al. Real-time detection of patients with acute HIV infection in Africa. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, February 22-25, 2005.
31. Stekler J, Sycks B, Holte S, et al. Semen HIV dynamics and effect of ART following primary HIV infection. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colorado, February 5-8, 2006.
32. Spira A.I., Marx P.A., Patterson B.K., et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 183 1 (1996) 215-225
33. Bogers W.M., Koornstra W.H., Dubbes R.H., et al. Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees. J Gen Virol 79 Pt 12 (1998) 2895-2903
34. Little S.J., McLean A.R., Spina C.A., et al. Viral dynamics of acute HIV-1 infection. J Exp Med 190 6 (1999) 841-850
35. Lindback S., Karlsson A.C., Mittler J., et al. Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS 14 15 (2000) 2283-2291
36. Stafford M.A., Corey L., Cao Y., et al. Modeling plasma virus concentration during primary HIV infection. J Theor Biol 203 3 (2000) 285-301
37. Finzi D., Hermankova M., Pierson T., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 5341 (1997) 1295-1300
38. Smith B.A., Gartner S., Liu Y., et al. Persistence of infectious HIV on follicular dendritic cells. J Immunol 166 1 (2001) 690-696
39. Zhang L., Ramratnam B., Tenner-Racz K., et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340 21 (1999) 1605-1613
40. Furtado M.R., Callaway D.S., Phair J.P., et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 340 21 (1999) 1614-1622
41. Weber J., Piontkivska H., and Quinones-Mateu M.E. HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Rev 8 2 (2006) 60-77
42. Brenchley J.M., Price D.A., and Douek D.C. HIV disease: fallout from a mucosal catastrophe?. Nat Immun 7 3 (2006) 235-239
43. Kornfeld C., Ploquin M.J., Pandrea I., et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest 115 4 (2005) 1082-1091
44. Deeks S.G., Kitchen C.M., Liu L., et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104 4 (2004) 942-947
45. Rybarczyk B.J., Montefiori D., Johnson P.R., et al. Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J Virol 78 7 (2004) 3561-3571
46. Henrard D.R., Daar E., Farzadegan H., et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 9 3 (1995) 305-310
47. Pilgrim A.K., Pantaleo G., Cohen O.J., et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 176 4 (1997) 924-932
48. Wei X., Decker J.M., Wang S., et al. Antibody neutralization and escape by HIV-1. Nature 422 6929 (2003) 307-312
49. Pellegrin I., Legrand E., Neau D., et al. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol 11 5 (1996) 438-447
50. Pullium J.K., Adams D.R., Jackson E., et al. Pig-tailed macaques infected with human immunodeficiency virus (HIV) type 2GB122 or simian/HIV89.6p express virus in semen during primary infection: new model for genital tract shedding and transmission. J Infect Dis 183 7 (2001) 1023-1030
51. Mattapallil J.J., Letvin N.L., and Roederer M. T-cell dynamics during acute SIV infection. AIDS 18 1 (2004) 13-23
52. Borrow P., Lewicki H., Wei X., et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3 2 (1997) 205-211
53. Letvin N.L., and Walker B.D. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 9 7 (2003) 861-866
54. Schmitz J.E., Kuroda M.J., Santra S., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 5403 (1999) 857-860
55. Koup R.A., Safrit J.T., Cao Y., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 7 (1994) 4650-4655
56. Goulder P.J., Brander C., Tang Y., et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412 6844 (2001) 334-338
57. Yu X.G., Addo M.M., Rosenberg E.S., et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol 76 17 (2002) 8690-8701
58. Goulder P.J., Altfeld M.A., Rosenberg E.S., et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 193 2 (2001) 181-194
59. Malhotra U., Berrey M.M., Huang Y., et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 181 1 (2000) 121-131
60. Richman D.D., Wrin T., Little S.J., et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 100 7 (2003) 4144-4149
61. Frost S.D., Wrin T., Smith D.M., et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 102 51 (2005) 18514-18519
62. Srivastava I.K., Ulmer J.B., and Barnett S.W. Role of neutralizing antibodies in protective immunity against HIV. Hum Vaccin 1 2 (2005) 45-60
63. Gonzalez E., Kulkarni H., Bolivar H., et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307 5714 (2005) 1434-1440
64. Kaslow R.A., Carrington M., Apple R., et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 2 4 (1996) 405-411
65. Malhotra U., Holte S., Dutta S., et al. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest 107 4 (2001) 505-517
66. Goulder P.J., Pasquier C., Holmes E.C., et al. Mother-to-child transmission of HIV infection and CTL escape through HLA-A2-SLYNTVATL epitope sequence variation. Immunol Lett 79 1-2 (2001) 109-116
67. *5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 97 6 (2000) 2709-2714
68. Connick E., Marr D.G., Zhang X.Q., et al. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retroviruses 12 12 (1996) 1129-1140
69. Mellors J.W., Kingsley L.A., Rinaldo Jr. C.R., et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 122 8 (1995) 573-579
70. Gao X., Nelson G.W., Karacki P., et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 344 22 (2001) 1668-1675
71. Rosenberg E.S., Altfeld M., Poon S.H., et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407 6803 (2000) 523-526
72. Rosenberg E.S., Billingsley J.M., Caliendo A.M., et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278 5342 (1997) 1447-1450
73. Pitcher C.J., Quittner C., Peterson D.M., et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 5 5 (1999) 518-525
74. Kalams S.A., Buchbinder S.P., Rosenberg E.S., et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 73 8 (1999) 6715-6720
75. Hecht F.M., Busch M.P., Rawal B., et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 16 8 (2002) 1119-1129
76. Celum C.L., Buchbinder S.P., Donnell D., et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis 183 1 (2001) 23-35
77. Schacker T., Collier A.C., Hughes J., et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 125 4 (1996) 257-264
78. Bollinger R.C., Brookmeyer R.S., Mehendale S.M., et al. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA 278 23 (1997) 2085-2089
79. Lavreys L., Thompson M.L., Martin Jr. H.L., et al. Primary human immunodeficiency virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis 30 3 (2000) 486-490
80. Kinloch-de Loes S., de Saussure P., Saurat J.H., et al. Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis 17 1 (1993) 59-65
81. Tindall B., Barker S., Donovan B., et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 148 4 (1988) 945-949
82. Kassutto S., and Rosenberg E.S. Primary HIV type 1 infection. Clin Infect Dis 38 10 (2004) 1447-1453
83. Kahn J.O., and Walker B.D. Acute human immunodeficiency virus type 1 infection. N Engl J Med 339 1 (1998) 33-39
84. Borrow P., Lewicki H., Hahn B.H., et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 9 (1994) 6103-6110
85. Douek D.C. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev 5 3 (2003) 172-177
86. Zaunders J.J., Moutouh-de Parseval L., Kitada S., et al. Polyclonal proliferation and apoptosis of CCR5+ T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2. J Infect Dis 187 11 (2003) 1735-1747
87. Zaunders J.J., Kaufmann G.R., Cunningham P.H., et al. Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection. J Infect Dis 183 5 (2001) 736-743
88. Lindback S., Brostrom C., Karlsson A., et al. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 10(6)/l, AIDS, and death from AIDS?. BMJ 309 6968 (1994) 1535-1537
89. Chan D.J. Fatal attraction: sex, sexually transmitted infections and HIV-1. Int J STD AIDS 17 10 (2006) 643-651
90. Osmond D.H., Page K., Wiley J., et al. HIV infection in homosexual and bisexual men 18 to 29 years of age: the San Francisco Young Men's Health Study. Am J Public Health 84 12 (1994) 1933-1937
91. Kim A.A., Kent C.K., and Klausner J.D. Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra, San Francisco 2000-2001. AIDS 16 10 (2002) 1425-1428
92. Buchacz K., McFarland W., Kellogg T.A., et al. Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. AIDS 19 13 (2005) 1423-1424
93. Reynolds S.J., and Quinn T.C. Developments in STD/HIV interactions: the intertwining epidemics of HIV and HSV-2. Infect Dis Clin North Am 19 2 (2005) 415-425
94. Gray R.H., Li X., Kigozi G., et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 366 9492 (2005) 1182-1188
95. Quinn T.C. Circumcision and HIV transmission. Curr Opin Infect Dis 20 1 (2007) 33-38
96. Drain P.K., Halperin D.T., Hughes J.P., et al. Male circumcision, religion, and infectious diseases: an ecologic analysis of 118 developing countries. BMC Infect Dis 6 1 (2006) 172
97. Rosen R.C., Catania J.A., Ehrhardt A.A., et al. The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention. J Sex Med 3 6 (2006) 960-975 [discussion 973-65]
98. Elder A., and Paterson C. Sharps injuries in UK health care: a review of injury rates, viral transmission and potential efficacy of safety devices. Occup Med (Lond) 56 8 (2006) 566-574
99. Moss A.R., Vranizan K., Gorter R., et al. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 8 2 (1994) 223-231
100. Sarkar S., Mookerjee P., Roy A., et al. Descriptive epidemiology of intravenous heroin users: a new risk group for transmission of HIV in India. J Infect 23 2 (1991) 201-207
101. Cardo D.M., Culver D.H., Ciesielski C.A., et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 337 21 (1997) 1485-1490
102. Weintrob A.C., Giner J., Menezes P., et al. Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med 163 17 (2003) 2097-2100
103. Rosenberg E.S., Caliendo A.M., and Walker B.D. Acute HIV infection among patients tested for mononucleosis. N Engl J Med 340 12 (1999) 969
104. Pincus J.M., Crosby S.S., Losina E., et al. Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center. Clin Infect Dis 37 12 (2003) 1699-1704
105. Fiscus S.A., Pilcher C.D., Miller W.C., et al. Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis 195 3 (2007) 416-424
106. Stekler J., Swenson P.D., Wood R.W., et al. Targeted screening for primary HIV infection through pooled HIV-RNA testing in men who have sex with men. AIDS 19 12 (2005) 1323-1325
107. Schupbach J. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA. AIDS Rev 4 2 (2002) 83-92
108. Schupbach J. Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success. Int Arch Allergy Immunol 132 3 (2003) 196-209
109. Pilcher C.D., McPherson J.T., Leone P.A., et al. Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA 288 2 (2002) 216-221
110. Stramer S.L., Glynn S.A., Kleinman S.H., et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 351 8 (2004) 760-768
111. Pilcher C.D., Fiscus S.A., Nguyen T.Q., et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 352 18 (2005) 1873-1883
112. Klausner J.D., Grant R.M., and Kent C.K. Detection of acute HIV infections. N Engl J Med 353 6 (2005) 631-633 [author reply 631-3]
113. Quinn T.C., Brookmeyer R., Kline R., et al. Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS 14 17 (2000) 2751-2757
114. Patel P., Klausner J.D., Bacon O.M., et al. Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr 42 1 (2006) 75-79
115. Priddy F.H., Pilcher C.D., Moore R.H., et al. Detection of Acute HIV Infections in an Urban HIV Counseling and Testing Population in the United States. J Acquir Immune Defic Syndr 44 2 (2007) 196-202
116. Smith D.E., Walker B.D., Cooper D.A., et al. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence?. AIDS 18 5 (2004) 709-718
117. Kinloch-De Loes S., Hirschel B.J., Hoen B., et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 333 7 (1995) 408-413
118. Niu M.T., Bethel J., Holodniy M., et al. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. J Infect Dis 178 1 (1998) 80-91
119. Lindback S., Vizzard J., Cooper D.A., et al. Long-term prognosis following zidovudine monotherapy in primary human immunodeficiency virus type 1 infection. J Infect Dis 179 6 (1999) 1549-1552
120. Berrey M.M., Schacker T., Collier A.C., et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 183 10 (2001) 1466-1475
121. Altfeld M., Rosenberg E.S., Shankarappa R., et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 193 2 (2001) 169-180
122. Babiker A., Darbyshire J., Pezzotti P., et al. Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. J Acquir Immune Defic Syndr 32 3 (2003) 303-310
123. Lacabaratz-Porret C., Urrutia A., Doisne J.M., et al. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis 187 5 (2003) 748-757
124. Oxenius A., Price D.A., Easterbrook P.J., et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 97 7 (2000) 3382-3387
125. Hare C.B., Pappalardo B.L., Busch M.P., et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 42 5 (2006) 700-708
126. Kassutto S., Maghsoudi K., Johnston M.N., et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 42 7 (2006) 1024-1031
127. Hammer S.M., Saag M.S., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 7 (2006) 827-843
128. Hecht F.M., Wang L., Collier A., et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 194 6 (2006) 725-733
129. Streeck H., Jessen H., Alter G., et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 194 6 (2006) 734-739
130. Markowitz M., Jin X., Hurley A., et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 186 5 (2002) 634-643
131. Fidler S., Oxenius A., Brady M., et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 16 15 (2002) 2049-2054
132. Hoen B., Fournier I., Lacabaratz C., et al. Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial. J Acquir Immune Defic Syndr 40 3 (2005) 307-316
133. Cohen D.E., and Walker B.D. Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection. Clin Infect Dis 32 12 (2001) 1756-1768
134. Imami N., Hardy G., and Gotch F. Development of immunotherapeutic strategies for HIV-1. Expert Opin Biol Ther 1 5 (2001) 803-816
135. Sereti I, Lane HC. Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies. Clin Infect Dis 15 2001;32(12):1738-55.
136. Pedersen C., Lindhardt B.O., Jensen B.L., et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 299 6692 (1989) 154-157
137. Pedersen C., Kolby P., Sindrup J., et al. The development of AIDS or AIDS-related conditions in a cohort of HIV antibody-positive homosexual men during a 3-year follow-up period. J Intern Med 225 6 (1989) 403-409
138. Lavreys L., Baeten J.M., Chohan V., et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 42 9 (2006) 1333-1339
139. Lori F., and Lisziewicz J. Targeting HIV reservoirs and reconstituting the immune system. Second annual meeting Research Institute for Genetic and Human Therapy April 18-19, 1999 Washington, DC. AIDS Res Hum Retroviruses 15 18 (1999) 1597-1617
140. Lori F., Jessen H., Lieberman J., et al. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 180 6 (1999) 1827-1832
141. Lafeuillade A., Poggi C., Hittinger G., et al. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis 188 10 (2003) 1426-1432
142. Subbarao S., Otten R.A., Ramos A., et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 194 7 (2006) 904-911
143. Lifson J.D., Piatak Jr. M., Cline A.N., et al. Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J Med Primatol 32 4-5 (2003) 201-210
144. Kaufmann G.R., Zaunders J.J., Cunningham P., et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 14 17 (2000) 2643-2651
145. Ngo-Giang-Huong N., Deveau C., Da Silva I., et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 15 6 (2001) 665-673
146. Yerly S., Gunthard H.F., Fagard C., et al. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 18 14 (2004) 1951-1953
147. Truong H.H., Grant R.M., McFarland W., et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 20 17 (2006) 2193-2197
148. Grant R.M., Hecht F.M., Warmerdam M., et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288 2 (2002) 181-188
149. Frost S, McCoy S, Hicks C, et al. Tracking molecular epidemiology in North Carolina, USA: The screening and tracing active transmission model. 14th Conference on Retroviruses and Opportunistic Infections 2007, Feb 25-28, Los Angeles, California. Session 56, Abstract# 240.
150. Little S.J., Daar E.S., D'Aquila R.T., et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282 12 (1999) 1142-1149
151. Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51 1 (1994) 8-19
152. Rabkin J.G., Ferrando S.J., Jacobsberg L.B., et al. Prevalence of axis I disorders in an AIDS cohort: a cross-sectional, controlled study. Compr Psychiatry 38 3 (1997) 146-154
153. Williams P., Narciso L., Browne G., et al. The prevalence, correlates, and costs of depression in people living with HIV/AIDS in Ontario: implications for service directions. AIDS Educ Prev 17 2 (2005) 119-130
154. Schrooten W., Dreezen C., Fleerackers Y., et al. Receiving a positive HIV test result: the experience of patients in Europe. HIV Med 2 4 (2001) 250-254
155. Department of Health. Guidelines for pre-test discussion on HIV testing. PL/CMO/(96)1 London: Department of Health, 1996.
156. Stekler J., Collier A.C., Holmes K.K., et al. Primary HIV infection education: knowledge and attitudes of HIV-negative men who have sex with men attending a public health sexually transmitted disease clinic. J Acquir Immune Defic Syndr 42 1 (2006) 123-126
157. Daar E.S., Moudgil T., Meyer R.D., et al. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 324 14 (1991) 961-964
158. Leynaert B., Downs A.M., and de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 148 1 (1998) 88-96
159. Yerly S., Vora S., Rizzardi P., et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 15 17 (2001) 2287-2292
160. Jacquez J.A., Koopman J.S., Simon C.P., et al. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 7 11 (1994) 1169-1184
161. Koopman J.S., Jacquez J.A., Welch G.W., et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol 14 3 (1997) 249-258
162. Wawer M.J., Gray R.H., Sewankambo N.K., et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191 9 (2005) 1403-1409
163. Cohen M.S., and Pilcher C.D. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis 191 9 (2005) 1391-1393
164. Pilcher C.D., Eron Jr. J.J., Vemazza P.L., et al. Sexual transmission during the incubation period of primary HIV infection. JAMA 286 14 (2001) 1713-1714
165. Fraser C, Hollingsworth T, Chapman R, Anderson RE. Quantifying the impact of primary infection on HIV transmission and control. 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colorado, February 5-8, 2006.
166. Colfax G.N., Buchbinder S.P., Cornelisse P.G., et al. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 16 11 (2002) 1529-1535
167. Pilcher C.D., Eaton L., Kalichman S., et al. Approaching HIV elimination: interventions for acute HIV infection. Curr HIV/AIDS Rep 3 4 (2006) 160-168
168. Brooks J.T., Robbins K.E., Youngpairoj A.S., et al. Molecular analysis of HIV strains from a cluster of worker infections in the adult film industry, Los Angeles 2004. AIDS 20 6 (2006) 923-928
169. Kelly J.A., and Kalichman S.C. Behavioral research in HIV/AIDS primary and secondary prevention: recent advances and future directions. J Consult Clin Psychol 70 3 (2002) 626-639
170. Simpson K, Biddle A, Leone PA, et al. Cost effectiveness of screening for acute HIV infection: the North Carolina STAT Program. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. 2006; Session 71, Abs# 374.
171. Center for HIV-AIDS vaccine immunology. Available at: http://www.chavi.org/. Accessed January 14, 2007.
172. Margolis D.M., and Archin N.M. Attacking HIV provirus: therapeutic strategies to disrupt persistent infection. Infect Disord Drug Targets 6 4 (2006) 369-376